- Home
- IOVA vs KZR Comparison
IOVA vs KZR Comparison
Compare IOVA & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- KZR
- Stock Information
- Founded
- IOVA 2007
- KZR 2015
- Country
- IOVA United States
- KZR United States
- Employees
- IOVA N/A
- KZR N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- KZR Health Care
- Exchange
- IOVA Nasdaq
- KZR Nasdaq
- Market Cap
- IOVA 1.0B
- KZR N/A
- IPO Year
- IOVA N/A
- KZR 2018
- Fundamental
- Price
- IOVA $1.75
- KZR $4.22
- Analyst Decision
- IOVA Strong Buy
- KZR Hold
- Analyst Count
- IOVA 9
- KZR 2
- Target Price
- IOVA $15.50
- KZR $9.00
- AVG Volume (30 Days)
- IOVA 13.9M
- KZR 36.1K
- Earning Date
- IOVA 05-08-2025
- KZR 05-20-2025
- Dividend Yield
- IOVA N/A
- KZR N/A
- EPS Growth
- IOVA N/A
- KZR N/A
- EPS
- IOVA N/A
- KZR N/A
- Revenue
- IOVA $212,679,000.00
- KZR N/A
- Revenue This Year
- IOVA $182.20
- KZR N/A
- Revenue Next Year
- IOVA $62.10
- KZR N/A
- P/E Ratio
- IOVA N/A
- KZR N/A
- Revenue Growth
- IOVA 11070.12
- KZR N/A
- 52 Week Low
- IOVA $2.70
- KZR $3.62
- 52 Week High
- IOVA $13.60
- KZR $9.20
- Technical
- Relative Strength Index (RSI)
- IOVA 23.78
- KZR 42.65
- Support Level
- IOVA $3.02
- KZR $3.82
- Resistance Level
- IOVA $3.31
- KZR $4.40
- Average True Range (ATR)
- IOVA 0.24
- KZR 0.27
- MACD
- IOVA -0.09
- KZR 0.02
- Stochastic Oscillator
- IOVA 4.81
- KZR 40.40
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.